title: Immunological effects of levamisole in vitro.
abstract: Levamisole, an anthelminthic drug with immunological properties, has recently been reported to have antitumor activity when administered with 5-fluorouracil in patients with Duke's C colorectal carcinoma. The mechanism of this antitumor effect is unknown, but has been postulated to be related to levamisole's immunomodulatory properties. To define further the immunomodulatory activities of levamisole, we studied the in vitro effects of levamisole on monocyte and lymphocyte cytotoxicity, activation, and proliferation; induction of cytokine-induced proteins; and expression of tumor-associated antigens. Experiments utilized peripheral blood mononuclear cells from normal donors incubated in the presence of increasing concentrations of levamisole (0.1 to 100 micrograms/ml). Levamisole had no consistent effect on induction of 2',5'-oligoadenylate synthetase activity or indoleamine-2,3-dioxygenase activity, or production of tumor necrosis factor. Levamisole had no effect on monocyte cytotoxicity or expression of HLA-DR, HLA-DQ, HLA-DP, and the Fc receptor. Similarly, levamisole had no significant effect on NK or LAK cytotoxicity or the immunological activation of T-lymphocytes, assessed by expression of CD3, CD4, CD8, CD16, CD25, and CD56. Proliferation of lymphocytes from normal donors, patients with benign polyps, and patients with malignancies, with or without IL-2 or irradiated LS174T cells, was not significantly increased overall. No significant enhancement in the expression of three tumor-associated antigens (880364, NRCO-4, and ING-1) and the intercellular adhesion molecule-1 (ICAM-1) antigen on four human cancer cell lines was observed following in vitro exposure to levamisole. We conclude that levamisole is not a potent modulator of the immune parameters we examined, and that the mechanism behind the unique clinical interaction between levamisole and 5-fluorouracil in colorectal carcinoma remains to be identified.
authors.affiliation: Department of Human Oncology, William S. Middleton Veterans Administration Hospital, Madison, WI 53705.
authors.forename: J H
authors.initials: JH
authors.lastname: Schiller
authors.forename: M
authors.initials: M
authors.lastname: Lindstrom
authors.forename: P L
authors.initials: PL
authors.lastname: Witt
authors.forename: J A
authors.initials: JA
authors.lastname: Hank
authors.forename: D
authors.initials: D
authors.lastname: Mahvi
authors.forename: R J
authors.initials: RJ
authors.lastname: Wagner
authors.forename: P
authors.initials: P
authors.lastname: Sondel
authors.forename: E C
authors.initials: EC
authors.lastname: Borden
mesh_terms: D015088:2',5'-Oligoadenylate Synthetase / Q000096:biosynthesis / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000032:analysis; D000954:Antigens, Surface / Q000032:analysis; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D003601:Cytotoxicity Tests, Immunologic; D006801:Humans; D016130:Immunophenotyping; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D007978:Levamisole / Q000494:pharmacology*; D008214:Lymphocytes / Q000187:drug effects; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D014366:Tryptophan Oxygenase / Q000096:biosynthesis / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000378:metabolism
chemical_list: D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D000970:Antineoplastic Agents; D014409:Tumor Necrosis Factor-alpha; D007978:Levamisole; D014366:Tryptophan Oxygenase; D015088:2',5'-Oligoadenylate Synthetase